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framework: protocol to determine a core
outcome set for efficacy and effectiveness
trials of alcohol screening and brief
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Abstract
Background: The evidence base to assess the efficacy and effectiveness of alcohol brief interventions (ABI) is
weakened by variation in the outcomes measured and by inconsistent reporting. The ‘Outcome Reporting in Brief
Intervention Trials: Alcohol’ (ORBITAL) project aims to develop a core outcome set (COS) and reporting guidance for
its use in future trials of ABI in a range of settings.
Methods/design: An international Special Interest Group was convened through INEBRIA (International Network
on Brief Interventions for Alcohol and Other Drugs) to inform the development of a COS for trials of ABI. ORBITAL will
incorporate a systematic review to map outcomes used in efficacy and effectiveness trials of ABI and their measurement
properties, using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) criteria.
This will support a multi-round Delphi study to prioritise outcomes. Delphi panellists will be drawn from a range of settings
and stakeholder groups, and the Delphi study will also be used to determine if a single COS is relevant for all settings. A
consensus meeting with key stakeholder representation will determine the final COS and associated guidance for its use in
trials of ABI.
Discussion: ORBITAL will develop a COS for alcohol screening and brief intervention trials, with outcomes stratified into
domains and guidance on outcome measurement instruments. The standardisation of ABI outcomes and their
measurement will support the ongoing development of ABI studies and a systematic synthesis of emerging research
findings. We will track the extent to which the COS delivers on this promise through an exploration of the use of the
guidance in the decade following COS publication.
Keywords: Consensus methods, Core outcome set, Delphi technique, Screening, Brief intervention, Alcohol, Measurement,
Alcohol brief intervention, Trial, Outcomes standardisation
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Background
As early as the start of the ‘WHO Collaborative Project
on Detection and Management of Alcohol-related Prob-
lems in Primary Health Care’ in the early 1980s [1],
researchers have recognised a need to address alcohol
problems across a wide spectrum of use levels from haz-
ardous use to dependence. Alcohol brief interventions
(ABIs) have emerged as the main approach to
addressing hazardous and harmful alcohol use in
primary health care, beginning with the results of the
DRAMS trial reported in 1987 [2]. However, ABIs
can be used in a range of settings beyond primary care
such as emergency departments [3, 4], general hospital
wards [5, 6], schools [7, 8], online [9, 10], criminal justice
[11, 12], and workplaces [13, 14].
ABIs vary in nature, ranging from very brief to more
extended models and can be delivered in a variety of
ways [15–17]. For the research presented here, we use
National Institute for Health and Care Excellence
(NICE) guidance PH24 [18] on the prevention and early
identification of alcohol-use disorders (including hazard-
ous drinking, harmful drinking and alcohol dependence)
among adults and adolescents (aged 16 + years) to guide
our definition of ABI. ABIs are defined as interventions
suitable for those not seeking treatment for an alcohol
problem but who are identified by screening as having,
or being at risk of, problems from their alcohol use.
ABIs are behavioural interventions that aim to help
someone reduce their alcohol consumption. They can
consist of short, often single sessions of feedback and
tailored advice (brief advice), or longer, motivationally
based interventions that explore motivations for drink-
ing and personal barriers to change (extended brief
intervention). PH24 recommends screening and brief
intervention for people aged 16 and above who are at
risk of, or experiencing, harm from alcohol and who are
not engaged in, or seeking treatment for, alcohol
dependence or alcohol-related problems. Although ABI
have been used by some in treatment contexts e.g.
[19] we use the PH24 definition.
Multiple systematic reviews and meta-analyses support
the effectiveness of ABIs in reducing alcohol use in pri-
mary health care [20–22]. However, research on ABI is
marked by conflicting findings regarding efficacy and ef-
fectiveness across primary health care, emergency ser-
vices, hospitals, criminal justice, workplaces, online, and
other settings [23–29]. An avoidable source of this con-
flict arises from the wide range of outcomes used to
measure alcohol-related and other relevant change. The
use of these different endpoints poses a challenge to
combining data in meta-analysis to ascertain efficacy
and effectiveness, and contribute to waste in research
[30]. The lack of consistency and standardisation in out-
comes also impedes the conduct of economic
evaluations in alcohol research [31]. The selection and
application of well-designed outcomes by trial steering
committees or other evaluation researchers [32] is rele-
vant to all stakeholders including service users, practi-
tioners and policymakers. Optimised measurement of
change will maximise the potential of ABI research to
influence decision-making, as it has in other research
areas such as rheumatoid arthritis [33, 34].
Systematic reviews summarising the effectiveness of a
wide range of health care interventions shows consider-
able heterogeneity in outcome measures used [35], and
research has also highlighted the problem of selective
and incomplete reporting [36] in Cochrane reviews. The
same is true for reviews of ABI delivered in a variety of
settings [20, 37–42]. As such, it is difficult to compare
findings of different research trials and other evalua-
tions, even though they aim to address similar research
questions. As replicability is essential to scientific
progress [43], the use of different instruments measuring
key outcomes in studies testing the same general
hypotheses impedes progress in the ABI field. Further-
more, if we aim for improved change measurement, a
reliance on statistical significance should be replaced by
precise estimates of differences, which is again
dependent on the use of common measures to compare
effect sizes. Meta-analysis is more accurate and inform-
ative when applied to a common metric rather than a
generalised effect size convention [44].
Both the Consolidated Standards of Reporting Trials
(CONSORT) Statement [45] and the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) Statement [46] recommend the use of a core
outcome set (COS), and draw upon the COMET
Initiative for guidance [35]. Developing a standard way
for authors to prepare and present trial findings ensures
complete and transparent reporting, which is essential to
critical appraisal and interpretation.
At the workshop ‘Design and conduct of randomised
controlled trials of brief interventions for alcohol and
drugs’ at the INEBRIA conference in Warsaw in 2014, it
was proposed to establish a Special Interest Group (SIG)
to consider ways to standardise measures used in research
on the efficacy and effectiveness of brief interventions.
This proposal was approved by the INEBRIA Coordinat-
ing Committee, leading to the formation of the INEBRIA
Research Measurement Standardisation Group and, later,
the Outcome Reporting in Brief Intervention Trials (OR-
BITAL) Group which, as of 2016, includes 29 members.
Aims and research questions
The primary aim of ORBITAL is to develop a COS for
ABI efficacy and effectiveness trials. The secondary aim
is to understand the variability in outcomes and meas-
urement instruments in existing trials across all settings
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and to organise this information in the most efficient
way for future trials of ABI in a published statement, the
‘ORBITAL Statement’.
The research questions are:
1. What domains, outcomes, and instruments have
been used in efficacy and effectiveness trials of ABI?
2. What outcomes are ranked by stakeholders as most
important for the ORBITAL COS?
3. What outcomes are relevant for different settings?
4. To what extent is the COS used in the decade
following its publication?
Methods/design
The first step in developing this COS will be to review
existing academic literature to identify outcomes orga-
nised by domain (‘what to measure’) and instruments
(‘how to measure’). Instruments will be rated in terms of
validity, reliability, responsiveness to change and usabil-
ity in ABI settings, effectively summarising and mapping
change measurement in the ABI field. The ratings will
be based on the COSMIN criteria [47]. This map of
change measurement will be presented to stakeholders
in the field, including patient and public representatives
(PPR) and beneficiaries of ABI. For this study, PPR are
advocates for those who are experiencing alcohol prob-
lems, hazardous or harmful drinkers, and those with
prior experience of dependence, some of whom may
have used an ABI in the past. This represents the range
of end users of ABIs. Priority outcomes will be identified
through Delphi consensus. The findings will be dis-
cussed and incorporated in the ORBITAL Statement of
reporting and measurement guidance on a COS orga-
nised into domains. Given the breadth of the settings in
which ABIs are implemented, the structure and content
of the final ORBITAL Statement is yet to be determined
since the COS might contain outcomes and instruments
that are applicable across all settings and content areas,
or there might be a core with a subset of outcomes and
instruments unique to a single setting or to specific con-
tent areas. The Delphi study and consensus meeting will
incorporate this decision-making element, and the
decision-making process will be carefully documented
and reviewed for potential bias.
The methods of this project comprise five phases.
Phase 1 consists of a systematic review to identify the
outcomes and instruments (ranked by COSMIN
criteria). Full details of this review can be found in
PROSPERO (registration number: CRD42016047185)
and will not be discussed further here. The second to
fifth phases, discussed below, are: (2) a Delphi study to
rank the outcomes in priority order; (3) a consensus
meeting to determine the final set and instruments; (4)
reporting and dissemination; and (5) an assessment of
the utility of the COS in the decade following the publi-
cation of the ORBITAL COS Statement.
Phase 2: Delphi study
To reduce the number of possible outcomes to a priority
list for discussion at a consensus meeting, we will use
the Delphi method. This is an iterative consensus
technique which comprises sequential questionnaires
answered anonymously by a range of relevant partici-
pants [48]. We will seek input from an international and
diverse stakeholder panel. A series of sequential
questionnaires will be presented in ‘rounds’. The Delphi
panel will comprise a range of stakeholders recruited
from the following groups who will be contacted directly
by email, with the suggestion to share the invitation to
participate with their colleagues. The stakeholders (some
of which overlap) include:
 Trial investigators – first and last authors of reports
of randomised trials in the field identified in the
systematic review
 Members of the INEBRIA SIG of the ORBITAL
project (which includes researchers in brief
interventions, methodologists, trialists, and health
professionals)
 Executive leadership of relevant scientific
organisations such as the Research Society on
Alcoholism, the Association for Medical Education
and Research in Substance Abuse, the Society for
the Study of Addiction to Alcohol and Other Drugs,
and the College on Problems of Drug Dependence
 Cochrane Review Group on Drugs and Alcohol
 NICE Alcohol-use Disorders: Prevention PH24
Membership Group
 People listed as being involved in ABI clinical
guidance including through the World Health
Organisation (WHO), the US Centers for Disease
Control and Prevention (CDC), the US Substance
Abuse and Mental Health Services Administration
(SAMHSA), the US National Institutes of Health
(NIH), and the National Board of Health and
Welfare (Sweden)
 Research funders acknowledged as funding the ABI
studies included in the review
 Journal editors and the Editorial Boards of journals
who are members of the International Society of
Addiction Journal Editors
 ABI academics who have experience of being on
Research Ethics Committees
 Statisticians, trialists, and COS developers
 Service users and service-user representatives
 Practitioners: including representatives from health,
education, alcohol and drug services, criminal
justice, and workplace health
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Panel size and recruitment
There are no accepted guidelines for panel size to
achieve stable consensus in a Delphi analysis. Like others
[49], we will be guided by practicality, scope, and time
available. We will aim to recruit and retain as large a
panel as possible. Participants will be invited to nomin-
ate others to contribute (snowball sampling). Individuals
will be identified through a range of contacts by
ORBITAL team members, including INEBRIA members.
The project manager (GS) and other members of the
Steering Group will invite participants from inter-
national stakeholder groups, using distribution lists such
as Addict-L, Addiction Medicine, Drug Misuse Research,
BALANCE, Alcohol Misuse (Scottish Addiction Studies),
Drugtalk, Ewodor, and the Kettil Bruun Society. Other
key methodologists will be reached through the UK
Hubs for Trials Methodology Research and Clinical
Trials Units in the UK. We will also recruit Delphi
panellists from the WHO Department of Mental Health
and Substance Abuse and from the US NIH, CDC, and
SAMHSA.
We aim to complete the Delphi analysis after two
rounds. However, if deemed necessary by the ORBITAL
Steering Group because of a clear lack of consensus we
will have a third round. We will reduce attrition between
rounds through the following techniques: a personalised
invitation, outline of timelines, personalised email
reminders (every 2 weeks, but with no more than four
reminders), and provision of an easy interface which
minimises the time required to complete each round
[49]. We will use online COMET software designed
specifically for the purposes of conducting Delphi
studies to generate COS. The importance of completing
all rounds will be emphasised to participants in the
Information Sheet.
The Delphi questionnaire and rounds
In round 1, participants will be asked to rate each out-
come using a scale of 1–9, with 1–3 labelled ‘not im-
portant for inclusion’, 4–6 labelled ‘important but not
critical’ and 7–9 labelled ‘critical for inclusion’ [49]. The
outcomes will be generated from the systematic review
in phase 1. Outcomes will be listed randomly, and
hosted on COMET software (DelphiManager), to avoid
leading participants to believe that some are more
important than others. PPR will be consulted in the
presentation and explanation of the outcomes. Partici-
pants also have the opportunity to add additional
outcomes and to comment on why they have ranked
outcomes as they have. Novel outcomes will be reviewed
and coded by at least two reviewers to determine if they
are indeed novel and cannot be subsumed into existing
outcomes; where there is disagreement, an additional
reviewer will be consulted.
All outcomes will be carried through to the second
round with first round scores displayed for each
outcome calculated as a percentage of responses split by
respondent group. Consensus is defined a priori as 70%
or more of the respondents scoring an outcome from 7
to 9 and fewer than 15% scoring it 1 to 3, in line with
similar studies [48–51]. All other score distributions
would be taken to indicate lack of agreement for inclu-
sion of a given outcome in the COS. The rationale for
this threshold reflects an outcome agreed by the major-
ity as critically important, with only a small minority
ranking an outcome as being of little or no importance.
Likewise, consensus that an outcome should not be in
the COS requires agreement by the majority that the
outcome is of little or no importance, with no more than
a small minority considering it to be critically important.
We recognise that choice of thresholds is somewhat
subjective, but specification of the definition in a study
protocol reduces the risk that researchers will define
consensus post hoc in a way that would bias the conclu-
sions toward their own beliefs [35].
Ethical considerations
Ethics approval will be sought from Teeside University
Ethics Committee to conduct the Delphi study.
Informed consent will be sought from all participants.
Individual participants will be approached or will volun-
teer themselves by the methods outlined above. They
will be sent a short email introducing the study, with
more information on the study and consent forms
available online. Information on the composition of the
Delphi panel will be collated, including age, background,
experience in years, field of interest, and current work-
ing location. Participants in the Delphi panel who agree
to be named will be listed in alphabetical order online,
and participants who request it will be emailed the final
ORBITAL Statement.
Phase 3: consensus meeting
After the Delphi study is completed, a convenience sam-
ple of representatives of the stakeholder groups will be
invited to join a consensus meeting to determine the
final COS. We will aim to include at least one person
from each stakeholder group, and understand that there
may be overlap. This is in keeping with guidance from
Tugwell et al. [30] and Prinsen et al. [34, 52]. The
consensus meeting will be recorded to evidence
decision-making. The meeting minutes will be available,
and a summary report will be published. The results of
the Delphi study on what to measure will be discussed
at the consensus meeting and representatives will be
asked to discuss ‘how’ the outcome variables in the COS
should be measured. If the number of outcomes priori-
tised in the Delphi study is too large to allow time to
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discuss the measurement of the COS items during the
main consensus meeting, a separate consensus meeting
may be held by teleconference to consider the COSMIN
rankings of each measure under each outcome. Given
that the number of domains will be unknown until the
Delphi is complete, a second Delphi may also be
proposed to rank the ‘how’ to measure under each of the
domains in the event that (1) there is limited evidence to
support ‘how’ to measure domains or (2) there are too
many measures under each domain to discuss at a
consensus meeting. Should this be required, a separate
protocol will be generated, and a separate ethics applica-
tion sought from Teeside University Ethics Committee.
The editors from key addiction journals will be invited
to discuss how best to use and disseminate the COS.
Phase 4: reporting and dissemination
The protocol for the ORBITAL COS has been registered
on the COMET Initiative website to prevent unnecessary
duplication of effort. Several subsequent ORBITAL pub-
lications are planned, including the results of the sys-
tematic review to identify what outcomes to measure
and the COSMIN ranking of how to measure them. The
Delphi study will also be written up for publication, not-
ing the changes to the list of outcomes suggested at each
stage. The consensus meeting will be documented and a
manuscript written describing any decision-making
challenges and how these were overcome. The papers re-
lating to the ORBITAL COS statment will be reported
using the COS-STAR guidance [53].
Phase 5: assessment of the uptake of the COS in future
trials
Subject to funding, regular checks on how the COS is
used over the subsequent decade will be carried out
using Google Scholar and Scopus. Alerts will be set up
to notify the team when the COS is cited and annual up-
dates will be reported to the INEBRIA Coordinating
Committee and the INEBRIA general membership at the
annual conference and via the INEBRIA Google Group.
Discussion
This protocol describes a programme of work to develop
a COS for assessing the efficacy and effectiveness of ABI
in clinical trials across all settings. The scope for the
COS is deliberately broad, given the wide variety of loca-
tions and types of ABI. This in itself is a challenge, and
the nature of the COS will depend greatly on the find-
ings of the systematic review. To the best of our know-
ledge, this will be the first Delphi study to ask for
comment on the suitability of outcomes across such a
wide range of settings, and to raise the possibility of
having a COS which is based around a core subset with
some sub-core aspects depending on the setting or
nature of the brief intervention. As such, the decision-
making process in developing the COS will need to be
clear on how and why decisions were made and by
whom [48]. Other innovative features of this protocol in-
clude the plan to follow up on the utility and use of the
COS and an a priori recognition that technological de-
velopments and changes in health care worldwide will
make it important to revisit the COS periodically, asses-
sing its continued utility for the contemporary ABI field.
Study status
As of April 2017, the systematic review (PROSPERO
registration number: CRD42016047185) has started. The
Delphi study has not yet begun, and a list of potential
participants is being collated.
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